Louis J Aronne

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7128869/louis-j-aronne-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113 papers	5,185 citations	34 h-index	71 g-index
118 ext. papers	6,422 ext. citations	7.4 avg, IF	5.66 L-index

#	Paper	IF	Citations
113	Reply to A Drewnowski et al, O Devinsky, D A Booth and E L Gibson, and D J Millward.. *American Journal of Clinical Nutrition*, **2022**, 115, 595-597	7	0
112	Telemedicine could be the solution to scaling obesity treatment.. *Obesity*, **2022**, 30, 573-574	8	
111	Weight Loss Outcomes With Telemedicine During COVID-19.. *Frontiers in Endocrinology*, **2022**, 13, 793290	5.7	0
110	Understanding the pathophysiologic pathways that underlie obesity and options for treatment.. *Expert Review of Endocrinology and Metabolism*, **2021**, 16, 321-338	4.1	1
109	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. *Journal of Medical Virology*, **2021**, 93, 4273-4279	19.7	16
108	Return on Investment: Medical Savings of an Employer-Sponsored Digital Intensive Lifestyle Intervention, Weight Loss. *Obesity*, **2021**, 29, 654-661	8	1
107	The Independent Risk of Obesity and Diabetes and Their Interaction in COVID-19: A Retrospective Cohort Study. *Obesity*, **2021**, 29, 971-975	8	6
106	Impact of Telemedicine During the COVID-19 Pandemic on Patient Attendance. *Obesity*, **2021**, 29, 1093-1094	8	2
105	Preadmission predictors of severe COVID-19 in patients with diabetes mellitus. *Journal of Diabetes and Its Complications*, **2021**, 35, 107967	3.2	1
104	Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1051-1057.e2	6.9	30
103	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. *Gastrointestinal Endoscopy*, **2021**, 93, 1110-1118	5.2	12
102	Use of Weight Loss Medications in Patients after Bariatric Surgery. *Current Obesity Reports*, **2021**, 10, 81-89	8.4	4
101	Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study. *Obesity Research and Clinical Practice*, **2021**, 15, 64-68	5.4	8
100	The carbohydrate-insulin model: a physiological perspective on the obesity pandemic. *American Journal of Clinical Nutrition*, **2021**,	7	37
99	Integrating an online weight management program with population health management in primary care: Design, methods, and baseline data from the PROPS randomized controlled trial (Partnerships for Reducing Overweight and Obesity with Patient-centered Strategies). *Contemporary Clinical Trials*, **2020**, 95, 106026	2.3	3
98	Joint international consensus statement for ending stigma of obesity. *Nature Medicine*, **2020**, 26, 485-497	30.5	210
97	Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. *International Journal of Obesity*, **2020**, 44, 990-998	5.5	2

96	Iatrogenic Obesity. *Endocrinology and Metabolism Clinics of North America*, **2020**, 49, 265-273	5.5	
95	Medical Weight-Loss Outcomes in Patients Receiving Concomitant Psychotropic Medication: A Retrospective Cohort Study. *Obesity*, **2020**, 28, 1671-1677	8	2
94	Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. *Surgery for Obesity and Related Diseases*, **2019**, 15, 1348-1354	3	31
93	It's Time for Multidisciplinary Obesity Management Centers. *Obesity*, **2019**, 27, 534	8	1
92	Efficacy of Endoscopic Interventions for the Management of Obesity: a Meta-analysis to Compare Endoscopic Sleeve Gastroplasty, AspireAssist, and Primary Obesity Surgery Endolumenal. *Obesity Surgery*, **2019**, 29, 2287-2298	3.7	31
91	The impact of food order on postprandial glycaemic excursions in prediabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 377-381	6.7	19
90	2097-P: Weight Loss Maintenance in Medically Managed Patients with Obesity. *Diabetes*, **2019**, 68, 2097-P	0.9	0
89	SAT-LB023 Elevated Fasting Plasma Glucose Predicts Higher Odds For Becoming A Super-responder With Gelesis100 In The GLOW Pivotal Weight-loss Study. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
88	MON-112 Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Have Obesity with High Insulin Resistance: Results of the GLOW Study. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
87	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 585-593	4	9
86	Current concepts in management of weight regain following bariatric surgery. *Expert Review of Endocrinology and Metabolism*, **2018**, 13, 67-76	4.1	21
85	Effect of Food Order on Ghrelin Suppression. *Diabetes Care*, **2018**, 41, e76-e77	14.6	2
84	Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1073-1080.e1	6.9	37
83	Devices and Endoscopic Bariatric Therapies for Obesity. *Current Obesity Reports*, **2018**, 7, 162-171	8.4	15
82	The challenge of meeting prescribed carbohydrate intake goals in low-carbohydrate diet studies. *American Journal of Clinical Nutrition*, **2018**, 107, 673-675	7	2
81	Intestinal and Gastric Origins for Diabetes Resolution After Bariatric Surgery. *Current Obesity Reports*, **2018**, 7, 139-146	8.4	8
80	Pharmacotherapy for obesity in individuals with type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 223-231	4	12
79	Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. *Obesity*, **2018**, 26, 332-339	8	46

78	Setting Up An Endobariatric Weight Loss Program. *American Journal of Gastroenterology*, **2018**, 113, 1567-1569	6.7	
77	Obesity Pharmacotherapy. *Medical Clinics of North America*, **2018**, 102, 135-148	7	68
76	Endoscopic Sleeve Gastroplasty, Laparoscopic Sleeve Gastrectomy, and Laparoscopic Band for Weight Loss: How Do They Compare?. *Journal of Gastrointestinal Surgery*, **2018**, 22, 267-273	3.3	68
75	Implementing an Online Weight-Management Intervention to an Employee Population: Initial Experience with Real Appeal. *Obesity*, **2018**, 26, 1704-1708	8	5
74	Weight Loss Medications in Older Adults After Bariatric Surgery for Weight Regain or Inadequate Weight Loss: A Multicenter Study. *Bariatric Surgical Patient Care*, **2018**, 13, 171-178	0.4	12
73	Weight Loss Medications in Young Adults after Bariatric Surgery for Weight Regain or Inadequate Weight Loss: A Multi-Center Study. *Children*, **2018**, 5,	2.8	17
72	Obesity: When to consider surgery. *Journal of Family Practice*, **2018**, 67, 614;616;618;620	0.2	1
71	Current and Future Medical Treatment of Obesity. *Gastrointestinal Endoscopy Clinics of North America*, **2017**, 27, 181-190	3.3	4
70	White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 631-649.e10	6.9	76
69	Practical Use of Pharmacotherapy for Obesity. *Gastroenterology*, **2017**, 152, 1765-1779	13.3	44
68	Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. *Obesity*, **2017**, 25, 857-865	8	30
67	Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. *Obesity Surgery*, **2017**, 27, 2649-2655	3.7	155
66	The American Board of Obesity Medicine: Five-year report. *Obesity*, **2017**, 25, 982-984	8	21
65	Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years. *New England Journal of Medicine*, **2017**, 376, 1995-6	59.2	9
64	Use of lorcaserin for glycemic control in patients with type 2 diabetes mellitus. *Obesity*, **2017**, 25, 816	8	1
63	Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. *American Journal of Gastroenterology*, **2017**, 112, 447-457	0.7	111
62	Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 504-510	6.9	140
61	Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested?. *Teaching and Learning in Medicine*, **2017**, 29, 123-128	3.4	21

60	Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2017**, 5, e000440	4.5	28
59	Is Obesity the New Hypertension? Parallels in the Evolution of Obesity and Hypertension as Recognized Disease States. *Current Atherosclerosis Reports*, **2017**, 19, 35	6	3
58	The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. *Surgery for Obesity and Related Diseases*, **2017**, 13, 491-500	3	90
57	Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. *Techniques in Gastrointestinal Endoscopy*, **2017**, 19, 12-17	0.8	7
56	Trimming the fat: endoscopic suturing for tightening of prior endoscopic sleeve gastroplasty. *Gastrointestinal Endoscopy*, **2017**, 85, 253-254	5.2	8
55	Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. *Expert Review of Clinical Pharmacology*, **2016**, 9, 27-34	3.8	9
54	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. *Current Atherosclerosis Reports*, **2016**, 18, 36	6	9
53	Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. *Obesity*, **2016**, 24, 1955-61	8	59
52	An update on naltrexone/bupropion extended-release in the treatment of obesity. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2235-2242	4	6
51	Pharmacotherapy for Obesity. *Endocrinology and Metabolism Clinics of North America*, **2016**, 45, 521-38	5.5	26
50	Drug-induced weight gain: Rethinking our choices. *Journal of Family Practice*, **2016**, 65, 780-788	0.2	8
49	Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. *Expert Opinion on Biological Therapy*, **2015**, 15, 1061-75	5.4	15
48	Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. *Endoscopy*, **2015**, 47, 164-6	3.4	87
47	Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels. *Diabetes Care*, **2015**, 38, e98-9	14.6	45
46	Endoscopic sleeve plication for revision of sleeve gastrectomy. *Gastrointestinal Endoscopy*, **2015**, 81, 1004	5.2	10
45	Efficacy comparison of medications approved for chronic weight management. *Obesity*, **2015**, 23 Suppl 1, S4-7	8	21
44	Treatment of obesity in 2015. *Journal of Cardiopulmonary Rehabilitation and Prevention*, **2015**, 35, 81-92	3.6	31
43	Lorcaserin Hcl for the treatment of obesity. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 2531-8	4	23

42	Response to Comment on Shukla et al. Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels. Diabetes Care 2015;38:e98-e99. *Diabetes Care*, **2015**, 38, e197	14.6	
41	Hypothalamic Inflammation: Is There Evidence for Human Obesity?. *Current Obesity Reports*, **2014**, 3, 242-7	8.4	3
40	Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. *Postgraduate Medicine*, **2014**, 126, 7-18	3.7	54
39	Recombinant human leptin does not alter gut hormone levels after gastric bypass but may attenuate sweet cravings. *International Journal of Endocrinology*, **2014**, 2014, 120286	2.7	5
38	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity*, **2013**, 21, 935-43	8	381
37	Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. *Obesity*, **2013**, 21, 2163-71	8	133
36	Weight loss treatment in obese adults--reply. *JAMA - Journal of the American Medical Association*, **2013**, 310, 2568	27.4	
35	Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. *Obesity*, **2013**, 21, 951-6	8	42
34	Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. *Current Atherosclerosis Reports*, **2012**, 14, 60-9	6	20
33	Causes of obesity. *Abdominal Radiology*, **2012**, 37, 730-2	3	133
32	Phentermine plus topiramate for the treatment of obesity. *Expert Review of Endocrinology and Metabolism*, **2012**, 7, 503-510	4.1	1
31	Implantable Gastric Stimulator Does Not Prevent the Increase in Plasma Ghrelin Levels That Occurs With Weight Loss. *Obesity*, **2011**, 19, 1935-1939	8	2
30	Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. *Obesity*, **2011**, 19, 1404-14	8	22
29	Emerging pharmacotherapy for obesity. *Expert Opinion on Emerging Drugs*, **2011**, 16, 587-96	3.7	20
28	Obesity Surgery: Patient Safety and Best Practices by SB Jones and D Jones. *Obesity*, **2010**, 18, 653-654	8	
27	Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. *Obesity*, **2010**, 18, 1739-46	8	74
26	Obesity as a disease state: a new paradigm for diagnosis and treatment. *Clinical Cornerstone*, **2009**, 9, 9-25; discussion 26-9		53
25	When prevention fails: obesity treatment strategies. *American Journal of Medicine*, **2009**, 122, S24-32	2.4	21

24	Ten putative contributors to the obesity epidemic. *Critical Reviews in Food Science and Nutrition*, **2009**, 49, 868-913	11.5	461
23	The challenge of treating obesity: the endocannabinoid system as a potential target. *Journal of the American Dietetic Association*, **2008**, 108, 823-31		11
22	The endocannabinoid system as a target for obesity treatment. *Clinical Cornerstone*, **2008**, 9, 52-64; discussion 65-6		8
21	Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. *Diabetes Care*, **2008**, 31, 1816-23	14.6	112
20	Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. *American Journal of Cardiology*, **2007**, 100, 18P-26P	3	10
19	Overweight and obesity: key components of cardiometabolic risk. *Clinical Cornerstone*, **2007**, 8, 29-37		39
18	Is rimonabant a safe and effective treatment for obesity?. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 388-9		3
17	Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 2977-83	5.6	130
16	The impact of obesity on cardiometabolic risk. *JAAPA: Official Journal of the American Academy of Physician Assistants*, **2007**, Suppl Endocannabinoid, 3-6	0.8	1
15	Therapeutic options for modifying cardiometabolic risk factors. *American Journal of Medicine*, **2007**, 120, S26-34	2.4	23
14	Weight Gain Induced by Psychotropic Drugs. *Obesity Management*, **2007**, 3, 165-169		3
13	Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2006**, 295, 761-75	27.4	916
12	Cardiovascular Risk Reduction: Focus on Managing Cardiometabolic Risk Factors. *Obesity*, **2006**, 14, 119S-120S		3
11	Pharmacological approaches to weight reduction: therapeutic targets. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 2616-21	5.6	73
10	Gastric pacing is not enough: additional measures for an effective obesity treatment program. *Obesity Surgery*, **2004**, 14 Suppl 1, S23-7	3.7	7
9	The emerging science of body weight regulation and its impact on obesity treatment. *Journal of Clinical Investigation*, **2003**, 111, 565-70	15.9	81
8	Weight gain in the treatment of mood disorders. *Journal of Clinical Psychiatry*, **2003**, 64 Suppl 8, 22-9	4.6	32
7	Adiposity and fat distribution outcome measures: assessment and clinical implications. *Obesity*, **2002**, 10 Suppl 1, 14S-21S		53

6	Obesity as a disease: etiology, treatment, and management considerations for the obese patient. *Obesity*, **2002**, 10 Suppl 2, 95S-96S		20
5	Classification of obesity and assessment of obesity-related health risks. *Obesity*, **2002**, 10 Suppl 2, 105S-115S		148
4	Obesity surgery: pros and cons. *Journal of Endocrinological Investigation*, **2002**, 25, 925-8	5.2	5
3	Reply to WJ McCarthy. *American Journal of Clinical Nutrition*, **2000**, 71, 847-848	7	0
2	Psychiatric illness in patients presenting for obesity treatment. *International Journal of Eating Disorders*, **1992**, 12, 63-71	6.3	51
1	Recent advances in therapies utilizing superabsorbent hydrogel technology for weight management: A review. *Obesity Science and Practice*,	2.6	0